AP775A - Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens. - Google Patents

Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens. Download PDF

Info

Publication number
AP775A
AP775A APAP/P/1997/000913A AP9700913A AP775A AP 775 A AP775 A AP 775A AP 9700913 A AP9700913 A AP 9700913A AP 775 A AP775 A AP 775A
Authority
AP
ARIPO
Prior art keywords
estrogen
level
effective
amount
gnrh antagonist
Prior art date
Application number
APAP/P/1997/000913A
Other languages
English (en)
Other versions
AP9700913A0 (en
Inventor
Gary D Hodgen
Original Assignee
The Eastern Virginia Medical School
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP775(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by The Eastern Virginia Medical School, Ortho Pharma Corp filed Critical The Eastern Virginia Medical School
Publication of AP9700913A0 publication Critical patent/AP9700913A0/xx
Application granted granted Critical
Publication of AP775A publication Critical patent/AP775A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
APAP/P/1997/000913A 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens. AP775A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number Publication Date
AP9700913A0 AP9700913A0 (en) 1997-01-31
AP775A true AP775A (en) 1999-10-28

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/000913A AP775A (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens.

Country Status (29)

Country Link
EP (1) EP0769956B1 (es)
JP (1) JP3138477B2 (es)
CN (1) CN1137722C (es)
AP (1) AP775A (es)
AT (1) ATE190494T1 (es)
AU (1) AU691952B2 (es)
BG (1) BG63363B1 (es)
BR (1) BR9508718A (es)
CA (1) CA2195745C (es)
CY (1) CY2228B1 (es)
CZ (1) CZ291803B6 (es)
DE (1) DE69515666T2 (es)
DK (1) DK0769956T3 (es)
EE (1) EE03515B1 (es)
ES (1) ES2145286T3 (es)
FI (1) FI970244L (es)
GR (1) GR3033590T3 (es)
HU (1) HU218910B (es)
IL (1) IL114655A (es)
IS (1) IS4413A (es)
LV (1) LV11823B (es)
MX (1) MX9700574A (es)
NO (1) NO970257D0 (es)
NZ (1) NZ290554A (es)
OA (1) OA10730A (es)
PT (1) PT769956E (es)
RU (1) RU2181598C2 (es)
SK (1) SK282118B6 (es)
WO (1) WO1996003138A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
PL201898B1 (pl) * 1999-09-23 2009-05-29 Zentaris Gmbh Zastosowanie antagonisty LH-RH w leczeniu endometriozy
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
AU2016264034B2 (en) * 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein

Also Published As

Publication number Publication date
CY2228B1 (en) 2003-04-18
IL114655A0 (en) 1995-11-27
FI970244A0 (fi) 1997-01-21
JP3138477B2 (ja) 2001-02-26
WO1996003138A1 (en) 1996-02-08
NZ290554A (en) 2000-08-25
PT769956E (pt) 2000-07-31
BG101158A (bg) 1997-09-30
SK7097A3 (en) 1997-11-05
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
JPH10503203A (ja) 1998-03-24
FI970244A7 (fi) 1997-01-21
AU691952B2 (en) 1998-05-28
DE69515666T2 (de) 2000-07-06
CN1200674A (zh) 1998-12-02
BR9508718A (pt) 1997-12-30
ES2145286T3 (es) 2000-07-01
NO970257L (no) 1997-01-21
MX9700574A (es) 1997-12-31
OA10730A (en) 2001-06-07
ATE190494T1 (de) 2000-04-15
SK282118B6 (sk) 2001-11-06
FI970244L (fi) 1997-01-21
NO970257D0 (no) 1997-01-21
CN1137722C (zh) 2004-02-11
LV11823B (en) 1998-03-20
LV11823A (lv) 1997-08-20
HUT77127A (hu) 1998-03-02
AU3132095A (en) 1996-02-22
CA2195745C (en) 2005-03-29
CZ15097A3 (en) 1997-11-12
IS4413A (is) 1997-01-14
DE69515666D1 (de) 2000-04-20
CZ291803B6 (cs) 2003-06-18
IL114655A (en) 2005-08-31
HU218910B (hu) 2000-12-28
EE9700208A (et) 1998-02-16
EP0769956B1 (en) 2000-03-15
BG63363B1 (bg) 2001-11-30
HU9700046D0 (en) 1997-02-28
EP0769956A1 (en) 1997-05-02
CA2195745A1 (en) 1996-02-08
AP9700913A0 (en) 1997-01-31
EE03515B1 (et) 2001-10-15
DK0769956T3 (da) 2000-06-05
RU2181598C2 (ru) 2002-04-27

Similar Documents

Publication Publication Date Title
EP0785792B1 (en) Treatment of ovarian estrogen dependent conditions
EP0686037B1 (en) Hormone replacement therapy
US8415332B2 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
AU691952B2 (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
US7309691B2 (en) Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders
Cedars et al. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction
US5658884A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
RU2360681C2 (ru) Композиция, содержащая комбинацию ингибитора ароматазы, прогестина и эстрогена, и ее применение для лечения эндометриоза
BG106442A (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
US5116818A (en) Method and kit for contraception with GnRH-antagonist
EP0378533A4 (en) Method and kit for contraception with gnrh-antagonist and progestin
Santen Perspectives for the clinical use of aromatase inhibitors